MeCHaNiSM Mechanical Characterisation of Nucleic Acids using Single Molecule Methods
- Coordinator
- Chalmers Tekniska Hogskola Aktiebolag, Sweden
- Runs
- 1 October 2024 to 30 September 2028
- Status
- Running
- EU funding
- €4.1m
- Total cost
- —
- Partners
- 12 organisations in 6 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101168851
What the project is doing
In the project's own words, from its summary on CORDIS.
Nucleic acid (NAs)-based therapies have started to yield major advances in the treatment of human disease. New approaches for understanding NA structure and function are required to extend the boundaries of today’s gene editing technologies, cancer therapies, and mRNA vaccines. Single-molecule techniques have revolutionised our understanding of NAs and their interactions with therapeutic oligonucleotides, small molecules, and proteins.
However, for Europe to remain competitive in this area, new expertise is urgently required in single-molecule NA analysis, which intersects the fields of physical chemistry, biophysics, NA synthesis, and computation. MeChaNiSM will train the next generation of European scientific leaders in the development and use of single-molecule biophysics techniques where they will investigate critical interrelated question regarding the structure, dynamics, function, and interactions of NAs.
To do this, our Doctoral Candidates (DCs) will:- Unravel high-resolution NA structures and intramolecular forces with modified bases- Understand the conformation and dynamics of NAs at the single-molecule level- Develop next-generation therapeutics for treating genetic diseasesMeChaNiSM connects world-leading researchers working in the fields of single-molecule biophysics, NA chemistry, and computational modeling with outstanding industrial partners working in complementary fields.
In addition to conducting world-class research, our DCs will understand industrial needs, have know-how in running multidisciplinary research, and will be immersed in a broad collaborative network connecting academia and industry. Our DCs will provide vital future breakthrough applications in NAs and single-molecule analysis to pharmaceutical and biotechnological industries where the design of new drugs - including NA-based therapeutics and vaccine technologies - will provide major improvements to human health.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Chalmers Tekniska Hogskola Aktiebolag | Goteborg | Sweden | Coordinator |
| Katholieke Universiteit Leuven | Leuven | Belgium | Participant |
| Nanotemper Technologies GmbH | Munchen | Germany | Associatedpartner |
| Universitaet Augsburg | Augsburg | Germany | Participant |
| Universitat Zu Koln | Koln | Germany | Participant |
| Universitat De Barcelona | Barcelona | Spain | Participant |
| Dublin City University | Dublin | Ireland | Participant |
| National Institute for Bioprocessing Research and Training Limited | Blackrock Dublin | Ireland | Associatedpartner |
| Lumicks BV | Amsterdam | Netherlands | Associatedpartner |
| Stichting Vu | Amsterdam | Netherlands | Participant |
| Universiteit Van Amsterdam | Amsterdam | Netherlands | Participant |
| Astrazeneca AB | Sodertaelje | Sweden | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI